Amyris has been granted a patent for methods to genetically engineer Kluyveromyces to produce and secrete antibodies. The invention involves modifying the host cell genome using nucleases and donor DNA molecules, resulting in the secretion of the desired polypeptide. GlobalData’s report on Amyris gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Amyris Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Amyris, Roll resistance tyre treads was a key innovation area identified from patents. Amyris's grant share as of February 2024 was 75%. Grant share is based on the ratio of number of grants to total number of patents.

Genetic engineering of kluyveromyces for antibody production

Source: United States Patent and Trademark Office (USPTO). Credit: Amyris Inc

A recently granted patent (Publication Number: US11884928B2) discloses a method for modifying a target site in a Kluyveromyces host cell genome. The method involves reducing non-homologous end joining (NHEJ) activity in the host cell by integrating a nucleic acid at YKU70 or YKU80. Subsequently, the host cell is contacted with a nuclease capable of cleaving the target site and a donor DNA molecule encoding a polypeptide for homologous recombination. This results in the integration of the donor DNA at the target site. Additionally, the method includes contacting the host cell with a linear nucleic acid for homologous recombination, converting it into a circular extrachromosomal nucleic acid with a selectable marker coding sequence. Finally, a transformed host cell secreting the encoded polypeptide is selected.

Furthermore, the patent claims include variations such as incorporating a stability element from K. marxianus in the circular extrachromosomal nucleic acid, adding a guide RNA coding sequence for nuclease targeting, and utilizing an RNA-guided DNA endonuclease with guide RNA introduction for precise targeting. The method also allows for contacting the host cell with a linear nucleic acid encoding a guide RNA for the RNA-guided DNA endonuclease. These claims highlight the versatility and specificity of the method for genetic modifications in Kluyveromyces host cells, offering potential applications in biotechnology and genetic engineering fields.

To know more about GlobalData’s detailed insights on Amyris, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.